Analyzing the serum concentrations of VEGF and HIF-1α in CTD-PAH patients and their correlations with relevant clinical indicators offers new avenues for early diagnosis, targeted and personalized treatment, and risk assessment of CTD-PAH. The gene discussed is VEGFA; the disease is pulmonary arterial hypertension.